Congratulations to Dr. Steven Schwendeman and Dr. Vishalakshi Krishnan on Two NIH SBIR Phase I Awards!

---

We are excited to highlight that ASKO Therapeutics, with Dr. Vishalakshi Krishnan as Principal Investigator and Dr. Steven Schwendeman (University of Michigan) as UM PI, has received two NIH SBIR Phase I awards to advance innovative controlled‑release drug delivery technologies:

1. R43GM157830 – “Paradigm‑changing, versatile, scalable and cost‑effective technology for monthly injections of peptide drugs”

2. R43GM159467 – “Novel injectable implants for long‑term local controlled release of therapeutic monoclonal antibodies”

Both awards are funded by the National Institute of General Medical Sciences (NIGMS) and reflect a productive collaboration between ASKO Therapeutics and the University of Michigan, leveraging recent advances in encapsulation and sustained release technologies.